Illumina forecasts strong 2022 revenue, signs four partnership deals

Reuters2022-01-11

Jan 10 (Reuters) - Illumina Inc on Monday forecast 2022 revenue above Wall Street estimates, counting on strong demand for its genetic sequencing products, and said it had signed collaboration ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2202627251?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2022-01-11 05:15","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2202627251","market":"us","top_or_hot":-1,"title":"Illumina forecasts strong 2022 revenue, signs four partnership deals","media":"Reuters","content":"<div>\n<p>Jan 10 (Reuters) - Illumina Inc on Monday forecast 2022 revenue above Wall Street estimates, counting on strong demand for its genetic sequencing products, and said it had signed collaboration ...</p>\n\n<a href=\"https://finance.yahoo.com/news/illumina-forecasts-strong-2022-revenue-211500655.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Illumina forecasts strong 2022 revenue, signs four partnership deals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIllumina forecasts strong 2022 revenue, signs four partnership deals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-11 05:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/illumina-forecasts-strong-2022-revenue-211500655.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Jan 10 (Reuters) - Illumina Inc on Monday forecast 2022 revenue above Wall Street estimates, counting on strong demand for its genetic sequencing products, and said it had signed collaboration ...</p>\n\n<a href=\"https://finance.yahoo.com/news/illumina-forecasts-strong-2022-revenue-211500655.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ILMN","symbol_name":"Illumina","start_time":0,"source_url":"https://finance.yahoo.com/news/illumina-forecasts-strong-2022-revenue-211500655.html","article_id":"2202627251","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2202627251","pubTimestamp":1641849300,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Jan 10 (Reuters) - Illumina Inc on Monday forecast 2022 revenue above Wall Street estimates, countin","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ILMN":"Illumina"},"translate_title":"Illumina预测2022年收入强劲，签署四项合作协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILMN":1},"content_text":"Jan 10 (Reuters) - Illumina Inc on Monday forecast 2022 revenue above Wall Street estimates, counting on strong demand for its genetic sequencing products, and said it had signed collaboration agreements with four healthcare companies. \n The company expects revenue of $5.15 billion to $5.24 billion in 2022, a growth of 14% to 16% year-over-year and higher than analysts' average estimate $4.90 billion, according Refinitiv IBES. \n It also posted a preliminary revenue estimate of about $4.52 billion for 2021 and announced a series of deals. \n The first was with breast cancer diagnostics company Agendia NV, to develop genome-based panel tests for cancer diagnosis. \n It also signed a deal with drugmaker Boehringer Ingelheim to identify which patients are best suited to its new medicines, and a collaboration agreement with UnitedHealth Group Inc's health services unit, Optum. \n Its fourth partnership was with Nashville Biosciences, a unit of Vanderbilt University Medical Center, for using the university's biobank of about 250,000 human DNA samples to improve medicine development. (Reporting by Leroy Leo; Editing by Devika Syamnath)","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2202627251"}